Dominant GNAO1 mutations cause an emerging group of childhood-onset neurological
disorders characterized by developmental delay, intellectual disability, movement disorders …

A long evolution of knowledge of the psychostimulant caffeine led in the 1960s to another
purine natural product, adenosine and its A2A receptor. Adenosine is a short‐lived …

The adenosine A2A receptor subtype is recognized as a non-dopaminergic
pharmacological target for the treatment of neurodegenerative disorders, notably …

Parkinson's disease (PD) is the second more common neurodegenerative disease with
increasing incidence worldwide associated to the population ageing. Despite increasing …

Purinergic receptors (Rs) of the ATP/ADP, UTP/UDP (P2X, P2Y) and adenosine (A1, A2A)-
sensitive classes broadly interfere with cognitive processes both under quasi normal and …

Dysfunction of goal-directed behaviors under stressful or pathological conditions results in
impaired decision-making and loss of flexibility of thoughts and behaviors, which underlie …

Mutations that constitutively activate G protein-coupled receptors (GPCRs), known as
constitutively activating mutations (CAMs), modify cell signaling and interfere with drugs …

Cellular responses to metabotropic glutamate (mGlu) receptor activation are shaped by
mechanisms of receptor-receptor interaction. mGlu receptor subtypes form homodimers …

Extracellular ATP can be a danger signal, but its role in striatal circuits afflicted in
Parkinson's disease (PD) is unclear and was now investigated. ATP was particularly …

Adenosine is an inhibitory modulator of neuronal excitability. Neuronal activity results in
increased adenosine release, thereby constraining excessive excitation. The exceptionally …